Related by context. All words. (Click for frequent words.) 89 clinical trials 79 Phase III clinical 76 Phase III trials 76 Phase III clinical trials 74 Phase IIb trial 74 Phase IIb 73 Phase 2b study 73 Phase 2b trial 72 phase IIa 71 phase IIb 71 Phase IIb clinical 71 Phase 2b clinical 71 Phase III 70 Phase IIa trial 70 phase IIb clinical 70 Phase 2a clinical 70 randomized clinical 70 phase IIa clinical 70 Phase IIa 69 Phase Ib clinical 69 multicenter clinical 69 pivotal Phase III 69 clinical 69 Phase IIa clinical 69 Phase Ib 69 Phase 2a trial 68 Phase 1b clinical 68 randomized controlled 68 Phase 1b trial 68 multicenter Phase II 67 multicenter study 67 dose escalation trial 67 multicenter 67 dose escalation study 67 Clinical Trial 67 preclinical 67 Phase IIIb clinical 67 phase IIb trial 66 placebo controlled clinical 66 investigational 66 clinical pharmacology studies 66 placebo controlled 66 Phase IIIb study 65 Phase IIIb 65 phase Ib 65 randomized placebo controlled 65 double blind placebo 65 Phase Ia 65 IIa trial 65 multicenter Phase 64 Phase #b/#a 64 randomized clinical trials 64 pharmacokinetic 64 randomized controlled trial 64 Phase 2b 64 confirmatory Phase III 64 Phase 2a 64 randomized Phase 64 Phase IIa trials 64 placebo controlled Phase 64 Phase IIb clinical trials 64 dose escalation 63 Phase 1b 63 pivotal Phase 63 oral deforolimus 63 Clinical trials 63 Phase Ib study 63 phase 2a 63 Phase III pivotal 63 dose escalation Phase 63 randomized Phase IIb 63 tremelimumab 63 Dacogen injection 63 investigational drug 63 KRN# 63 placebo controlled Phase III 62 Phase IIB 62 preclinical studies 62 midstage studies 62 Phase IIb trials 62 prospective observational 62 randomized multicenter 62 randomized trials 62 efficacy 62 registrational 62 teduglutide 62 randomized controlled clinical 62 COMFORT II 62 dose escalation clinical 62 double blinded randomized 62 Phase Ib II 62 IIa clinical trial 62 midstage trials 62 pharmacokinetic PK study 62 SUCCEED trial 62 Phase Ib clinical trials 62 rALLy trial 62 BRIM3 62 JAK inhibitor 62 ADVANCE PD 62 randomized double 62 Phase 1a clinical 62 SYMMETRY trial 62 Phase 1a 62 NO# [002] 62 multiple ascending dose 62 ENDEAVOR IV 62 INCB# [001] 62 unblinding 62 ABSORB trial 62 Phase III randomized 61 rALLy clinical trial 61 PREOS 61 PEARL SC 61 Asentar 61 IIa clinical 61 Phase II 61 DSMB 61 phase IIb study 61 HCV SPRINT 61 Corlux 61 Phase 2b clinical trials 61 double blinded placebo 61 prospective randomized 61 multicenter phase 61 randomized Phase III 61 placebo controlled studies 61 Phase 2b kidney transplant 61 Phase IIb III 61 Phase III randomized controlled 61 oral ridaforolimus 61 Phase III psoriasis 61 pivotal bioequivalence 61 Amrubicin 61 OLYMPIA registry 60 tolevamer 60 phase IIIb 60 ToGA 60 multicenter trials 60 pharmacokinetic studies 60 investigational compound 60 Allovectin 7 60 PSN# [002] 60 tolerability 60 axitinib 60 PROPEL trial 60 VITAL Trial 60 lintuzumab 60 BRIM2 60 ganetespib 60 placebo controlled randomized 60 neratinib 60 Phase III VISTA 60 Phase #/#a 60 multicenter prospective 60 HPTN 60 randomized controlled clinical trials 60 BLA submission 60 multicentre randomized 60 Factor VIIa 60 elotuzumab 60 alvespimycin 60 Phase Ib IIa clinical 60 randomized multicenter Phase III 60 multicenter randomized placebo controlled 60 Phase #b/#a trial 60 MADIT II 60 midstage study 59 mipomersen 59 viral kinetic 59 phase Ib clinical 59 prospective multicenter 59 HuMax CD# 59 APEX PD 59 RSD# oral 59 PEG PAL 59 Bronchitol 59 confirmatory clinical 59 placebo controlled clinical trials 59 ADAGIO study 59 PFO migraine 59 IL# PE#QQR 59 multicentre 59 Aryplase 59 Allovectin 7 ® 59 unblinded 59 single ascending dose 59 GLP toxicology studies 59 Viprinex 59 HuMax CD4 59 vemurafenib 59 blind randomized placebo 59 Azedra 59 randomized blinded 59 ELACYT 59 multicentre study 59 celgosivir 59 TELCYTA 59 trastuzumab DM1 59 SPIRIT III 59 randomized 59 HGS# 59 pharmacokinetic PK 59 aflibercept 59 forodesine 59 placebo controlled trials 59 Medidur TM FA 59 glufosfamide 59 ataluren 59 tanespimycin 59 riociguat 59 multicenter randomized controlled 59 Mipomersen 59 OHR/AVR# 59 BETAS 59 dirucotide 59 AZILECT R 59 Nexavar sorafenib 59 MIST II 59 GAMMAGARD 59 ONTARGET 59 bicifadine 59 multicenter clinical trials 59 prospective randomized placebo 59 nonclinical studies 59 Phenoptin 59 Onrigin 59 VEGF Trap 59 NP2 Enkephalin 59 methylnaltrexone 59 ILLUMINATE 59 Fodosine 58 dirucotide MBP# 58 AZILECT ® 58 thorough QT 58 preclinical efficacy 58 IIa clinical trials 58 ELCAP 58 ocrelizumab 58 BLA filing 58 alogliptin 58 AEGR 58 EOquin TM 58 registrational trial 58 phase IIb III 58 cediranib 58 lorvotuzumab mertansine 58 VNP#M 58 LibiGel Phase III 58 APPRAISE 58 enzastaurin 58 RE LY 58 daclizumab 58 EOquin 58 valopicitabine 58 Canvaxin 58 CoFactor 58 IND submission 58 EMPHASIS HF trial 58 isavuconazole 58 arzoxifene 58 Clinical Study 58 clofarabine 58 CLARITY study 58 Trofex 58 cannabinor 58 Phase IIa clinical trials 58 MERLIN TIMI 58 confirmatory Phase 3 58 Rezular 58 Cloretazine ® 58 clevidipine 58 OvaRex ® MAb 58 Omigard 58 Pivotal Trial 58 sorafenib Nexavar 58 sunitinib 58 sunitinib malate 58 trastuzumab DM1 T DM1 58 Board DSMB 58 CHAMPION PCI 58 unblind 58 ENESTnd 58 Amigal 58 RE LY ® 58 ISIS # 58 pertuzumab 58 TLK# 58 midstage clinical 58 randomized controlled trials 58 bevacizumab Avastin 58 CRLX# 58 Urocidin 58 Cloretazine R VNP#M 58 Desmoteplase 58 Phase III TRIST 58 MAGE A3 ASCI 58 PANVAC VF 58 dose cohorts 58 Phase IIb kidney transplant 58 dalbavancin 58 integrase inhibitor 58 Proellex TM 58 ENRICH trial 58 pharmacodynamics 58 orBec 58 II Clinical Trial 58 NSABP 58 blinatumomab 58 ASCEND HF 58 Fx #A 58 blind randomized 58 phase III ACCLAIM 57 clazosentan 57 ReN# 57 HCV RESPOND 2 57 MyVax 57 blinded randomized 57 GALNS 57 SUTENT ® 57 UPLYSO 57 ProSavin 57 PEG Interferon lambda 57 ASA# 57 CLIRS trial 57 depsipeptide 57 IMPROVE IT 57 deforolimus 57 TG MV 57 SPIRIT IV 57 YONDELIS 57 Myocet 57 blinded placebo controlled 57 ascending dose 57 peginesatide 57 multicenter randomized double 57 Sulonex 57 dose cohort 57 European Sepsis Trial 57 Sorafenib HCC Assessment 57 Menerba 57 liprotamase 57 AVERROES 57 picoplatin 57 ProLindac 57 FOLOTYN ® 57 BrachySil TM 57 reslizumab 57 TQT studies 57 AQ4N 57 cathepsin K inhibitor 57 PROSTVAC TM 57 ORMD 57 RG# [001] 57 Tyrima 57 OncoVEX GM CSF 57 preclinical toxicology 57 figitumumab 57 nonrandomized 57 ANCHOR trial 57 retrospective observational study 57 Zenvia Phase III 57 Phase 2a clinical trials 57 MEND CABG 57 Phase III Clinical Trials 57 EVEREST II 57 Memryte 57 TMC# [002] 57 Elocalcitol 57 eniluracil 57 TMC# C# 57 denufosol 57 Clinical Trials 57 eltrombopag 57 randomized controlled Phase 57 Cloretazine 57 Ixempra 57 mertansine 57 LUX Lung 57 telaprevir 57 ixabepilone 57 REALITY Trial 57 AzaSite Plus 57 LymphoStat B TM 57 alvimopan 57 prospective randomized multicenter 57 Plicera 57 IPLEX 57 Exherin TM 57 Hyphanox 57 QLT# 57 efficacy tolerability 57 ATIR TM 57 ruxolitinib 57 JAK2 inhibitor 57 dexpramipexole 57 active comparator 57 Zybrestat 57 EFAPROXYN 57 trials RCTs 57 Diamyd ® 57 PROMACTA 57 TAXUS IV 57 IDX# 57 PROSTVAC ® 57 BrachySil 57 diabetic neuropathic pain 57 fostamatinib 57 budesonide foam 57 gefitinib Iressa 57 clevudine 57 AVADO 57 DermaVir Patch 57 BRAF inhibitor 57 HuMax EGFr 57 EDEMA3 57 IMA# 57 cardio renal 57 ancrod 57 Stimuvax 57 Aplidin 57 NSABP C 57 MYDICAR 57 Xinlay 57 clinicaltrials 57 GVAX 57 prospective randomized controlled 57 Plenaxis TM 57 XL# SAR# 57 fidaxomicin Phase 3 57 Sutent sunitinib 57 pain palliation 57 AeroLEF TM 57 blind placebo controlled 57 Phase #b/#a clinical 57 biologic 56 Icatibant 56 Advexin 56 RhuDex 56 lomitapide 56 bioabsorbable stent 56 Phase 1b clinical trials 56 masked placebo controlled 56 Rheos System 56 NCCTG 56 antisense drug 56 IIa trials 56 midstage clinical trials 56 atrasentan 56 cangrelor 56 OncoVEX 56 afamelanotide 56 Lupuzor 56 denosumab 56 BAY #-# 56 Proxinium TM 56 StemEx R 56 Fablyn 56 OncoVex 56 IMC A# 56 ganaxolone 56 pitavastatin 56 cetrorelix 56 randomized multicenter trial 56 perifosine 56 PXD# 56 Urocortin 2 56 LCP AtorFen 56 Augment Injectable 56 oral prodrug 56 Atrasentan 56 EmbraceAC 56 torezolid phosphate 56 amrubicin 56 TASKi3 56 assessing T DM1 56 Zelrix 56 bortezomib Velcade 56 number NCT# ClinicalTrials.gov 56 Tarvacin TM 56 OvaRex R 56 EchoCRT 56 Investigational 56 Nasulin 56 postapproval 56 Civacir 56 IMC #B 56 treatment naive genotype 56 teriflunomide 56 APEX AMI trial 56 multicenter randomized 56 eprotirome 56 MOZOBIL 56 pegloticase 56 Investigational Device Exemption IDE 56 obatoclax 56 pomalidomide 56 Zerenex 56 Neuradiab 56 MBP# [001] 56 randomized Phase 2b 56 PRX # 56 relapsed multiple myeloma 56 Genasense ® 56 dacetuzumab 56 oral methylnaltrexone 56 tesmilifene 56 PRIMO CABG2 56 Quinamed 56 ACCLAIM trial 56 LymphoStat B 56 Solazed 56 INTERCEPT platelets 56 Phase III Clinical Trial 56 DR Cysteamine 56 Hepatocellular Carcinoma HCC 56 PDE4 inhibitor 56 REOLYSIN ® 56 label multicenter 56 personalized immunotherapy 56 PRE SURGE 56 TACI Ig 56 Orazol 56 Ostarine 56 Clinical Antipsychotic Trials 56 bardoxolone 56 Gabapentin GR 56 Itopride 56 evaluating tivozanib 56 HGS ETR1 56 Ocrelizumab 56 sulodexide 56 prospective nonrandomized 56 PRTX 56 Torisel 56 trastuzumab emtansine T DM1 56 rNAPc2 56 HORIZONS AMI trial 56 AP# [003] 56 ofatumumab HuMax CD# 56 Alpharadin 56 EVIZON TM 56 BST CarGel R 56 teplizumab 56 substudy 56 Marqibo 56 Glybera R 56 Arranon 56 Abiraterone 56 brivaracetam 56 EORTC 56 PRECISE trial 56 DAPT 56 CALGB 56 omacetaxine mepesuccinate 56 ZYBRESTAT 56 SEPET TM 56 Cogane 56 GLPG# 56 AIR2 Trial 56 Viramidine 56 Archexin 56 Motesanib 56 blinded randomized placebo controlled 56 Kynapid 56 GEM OS1 56 BCX# 56 Ereska 56 Novartis Zometa 56 Laquinimod 56 BR.# 56 KNS # 56 IMGN# 56 immunotherapeutic vaccine 56 efficacy endpoint 56 INS# [001] 56 ZFP Therapeutic 56 STRIDE PD 56 bendamustine 56 RE COVER 56 VALOR trial 56 EGS# 56 LibiGel ® 56 Androxal TM 56 dexanabinol 56 galiximab 56 CR# vcMMAE 56 noninfectious uveitis 56 Hedgehog antagonist 56 lumiliximab 56 vicriviroc 56 AIM HIGH 56 LEUKINE 56 Relovair 56 controlled multicenter 56 sNDA submission 56 Ceflatonin 56 Ketotransdel 55 phase III SIMPADICO 55 SNT MC# 55 Safinamide 55 NDA submission 55 Phase III confirmatory 55 PFO closure 55 immunogenicity 55 ongoing Phase 1b 55 CDP# 55 label dose escalation 55 Velcade bortezomib 55 observational study 55 nimotuzumab 55 Cethrin 55 pharmacokinetics PK 55 elesclomol 55 Neurostep TM 55 HeFT 55 clinical endpoints 55 DAPT Study 55 midstage clinical trial 55 multicenter Phase III 55 Phase IIa proof 55 histone deacetylase HDAC inhibitor 55 ASSERT trial 55 Telcyta 55 Adlea 55 Degarelix 55 AIR inhaled insulin 55 multicenter randomized clinical 55 metastatic sarcomas 55 VADT 55 Zalbin 55 torcetrapib atorvastatin 55 iniparib 55 BCIRG 55 entinostat 55 albinterferon alfa 2b 55 lorcaserin Phase 55 Zenvia ™ 55 CUSTOM III 55 Varisolve 55 CARE HF 55 Amplimexon 55 Ceplene 55 Zolinza 55 ORENCIA R 55 TOCOSOL Paclitaxel 55 HQK 55 CALGB # [002] 55 bioequivalence 55 ZoMaxx 55 R#/MEM # 55 darusentan 55 ALTU 55 elacytarabine 55 AIR CF2 55 Mepact 55 Trimesta 55 PRIMO CABG 55 TBC# 55 Phase III Trial 55 Alzhemed TM 55 elagolix 55 Diamyd r vaccine 55 CEQ# 55 TELINTRA 55 senicapoc 55 OVATURE trial 55 ZACTIMA 55 CB2 selective receptor agonist 55 Onconase 55 ponatinib 55 generation PNP inhibitor 55 L BLP# 55 Edwards SAPIEN valve 55 Institutional Review 55 cetrorelix pamoate 55 Tarceva TM 55 SUTENT 55 RE LY trial 55 HspE7 55 ATTRACT 55 Prochymal 55 AZX# 55 Certican 55 multidose 55 Arzerra ofatumumab 55 Aflibercept 55 ThermoDox R 55 COU AA 55 Oglemilast 55 Actilon 55 NEUMUNE 55 Tolamba 55 refractory CLL 55 Phase III HEAT 55 varespladib 55 visilizumab 55 farletuzumab 55 subcutaneous formulation 55 BNC# 55 Vernakalant 55 TAXUS VI 55 Rasilez Tekturna 55 Phase III metastatic melanoma 55 BioNumerik 55 incyclinide 55 AEG# 55 dosing cohorts 55 NV1FGF 55 fenretinide 55 CRx 55 Solorel 55 Preos 55 Aurexis 55 CardioFit 55 TRO# 55 LUMINATE 55 DPP4 inhibitor 55 Raptiva R 55 PrevOnco 55 Pimavanserin 55 Acapodene 55 ALN VSP Phase 55 TAXUS TM 55 PRECISE Trial 55 pralatrexate 55 interferon beta 1b 55 Pivotal Clinical Trial 55 investigational pan BCR 55 Phase 55 AVN# [001] 55 satraplatin 55 multicenter placebo controlled 55 FDA Investigational Device 55 Drug Eluting Stent System 55 registrational studies 55 Sym# 55 MGd 55 GRN# 55 talactoferrin 55 DXL# 55 viral kinetics 55 afatinib 55 fosbretabulin 55 palifosfamide 55 nab paclitaxel 55 PS# [001] 55 selective androgen receptor modulator 55 IMPROVE HF 55 Prostate AdenoCarcinoma Treatment 55 tivozanib 55 Initiated Phase 55 Zilver PTX 55 Spiegelmer ® 55 anidulafungin 55 Affinitak 55 motesanib 55 multicentre randomized double 55 olaparib 55 NABTT 55 vosaroxin 55 MEND CABG II 55 ePRO 55 pregabalin Lyrica 55 mapatumumab 55 romiplostim 55 UVIDEM 55 dose dose escalation 55 DSMB recommended 55 Alzhemed 55 ELND# 55 TKM ApoB 55 tramiprosate Alzhemed TM 55 relapsing remitting multiple sclerosis 55 AERx iDMS 55 vismodegib 55 severe hypercholesterolemia 55 recurrent glioblastoma multiforme 55 RRMS patients 55 Dapagliflozin 55 T DM1 55 Iluvien 55 PF # [002] 55 investigational therapies 55 liposomal formulation 55 ACUITY trial 55 Phase 2b randomized 55 Phase III Pivotal 55 recurrent GBM 55 OvaRex 55 Virulizin R 55 Phase #/#a trial 55 MyVax R 55 Intervention Effectiveness 55 betrixaban 55 Hydroxyurea 55 GSK# [002] 55 velaglucerase alfa 55 zalutumumab 55 Zavesca R 55 oral rivaroxaban 55 Edge STudy 55 drug eluting coronary stent 55 Phase Ib IIa 55 cetuximab Erbitux 55 CRMD# 55 tasocitinib 55 alemtuzumab MS 55 StaphVax 55 MAXY alpha 55 glatiramer acetate 55 randomized multicentre 55 Prodarsan ® 55 ABSORB clinical 54 paclitaxel poliglumex 54 AIR CF1 54 pharmacokinetic characteristics 54 Traficet EN 54 MAA submission 54 IND enabling 54 MORAb 54 EVIZON 54 StemEx 54 OncoGel 54 Aptivus 54 tafamidis 54 TOLAMBA 54 preclinically 54 subanalysis 54 CA4P 54 cancer neuroendocrine tumor 54 novel oral anticoagulant 54 CytoFabTM 54 IIb clinical trial 54 Enobia 54 pediatric glioma 54 APTIVUS 54 carfilzomib 54 Sebivo 54 pazopanib 54 huC# DM4 54 Dalbavancin 54 antibody MAb 54 Fabry Disease 54 Acetavance 54 abiraterone 54 PARTNER Trial 54 Prosaptide 54 Promacta 54 recurrent glioma 54 ozarelix 54 omecamtiv mecarbil 54 recurrent malignant glioma 54 myoblast therapy 54 Erbitux cetuximab 54 randomized crossover 54 Bicifadine 54 everolimus eluting stent 54 Aurora kinase inhibitor 54 oxymorphone ER 54 investigational protease inhibitor 54 relapsing multiple sclerosis 54 REG1 54 eliglustat tartrate 54 Alocrest 54 Anthim 54 PHX# 54 custirsen 54 evaluating REVLIMID 54 MyVax personalized immunotherapy 54 vandetanib 54 Genz # 54 StaphVAX 54 investigational hepatitis C 54 Campath alemtuzumab 54 NOX E# 54 therapeutic monoclonal antibody 54 etanercept Enbrel 54 Gattex 54 phase III isavuconazole 54 zanolimumab 54 ustekinumab 54 Neuvenge 54 velafermin 54 Nuvion 54 CYT# 54 EMPOWER ™ 54 MIS# 54 perifosine KRX 54 almorexant 54 rFVIIa 54 dimebon 54 docetaxel Taxotere R 54 Omacetaxine 54 CURRENT OASIS 7 54 Intarcia 54 RE SURGE 54 TPI ASM8 54 prospective multicentre 54 Ophena 54 Hycamtin 54 ridaforolimus 54 Zoraxel 54 Entereg 54 Azilect ® 54 voreloxin 54 iPrEx 54 otelixizumab 54 Phase III multicenter 54 candidates Dyloject TM 54 Clolar 54 PDX pralatrexate 54 ITAX 54 tipranavir 54 LEP ETU 54 Stimuvax R 54 PMA submission 54 SparVax TM 54 non nucleoside HCV 54 Cannabinor 54 CCR5 antagonist 54 Trexima 54 crizotinib PF # 54 Tracleer R 54 Cimzia TM 54 miglustat 54 Prostate Lung Colorectal 54 IV metastatic melanoma 54 GetGoal Phase III 54 VICTOR E1 54 acute ischemic stroke 54 crizotinib 54 Pivotal Phase III 54 opioid induced bowel dysfunction 54 DU #b 54 apremilast 54 SCD HeFT 54 IRX 2 54 TRISENOX 54 pharmacodynamic effects 54 Augment Bone Graft 54 Allovectin 7 R 54 Vectibix panitumumab 54 Trovax 54 hypoxia activated prodrug 54 CINTREDEKIN BESUDOTOX 54 Triolex 54 noninferiority 54 dermaPACE TM 54 prospective multicenter study 54 maximally tolerated dose 54 IMPACT DCM clinical 54 oral treprostinil 54 Fibrillex TM 54 monotherapy 54 Vion Pharmaceuticals 54 LBH# 54 ThGRF 54 Removab 54 MabThera rituximab 54 RezularTM 54 oral FTY# 54 VIR# 54 Vectibix 54 sorafenib 54 SABCS 54 MYCAMINE 54 GRNVAC1 54 Pervasis 54 subgroup analyzes 54 apaziquone 54 Oral NKTR 54 FOLOTYN 54 Phase IIA 54 FM VP4 54 ofatumumab 54 Virulizin ® 54 dosing regimens 54 nitazoxanide 54 maribavir 54 confirmatory Phase 54 Tolvaptan 54 ALGRX 54 pharmacokinetic pharmacodynamic 54 Egrifta 54 Emselex 54 Cethromycin 54 INCB# [002] 54 efficacy endpoints 54 safety tolerability pharmacokinetics 54 RSD# 54 Provenge prostate cancer 54 MGCD# [001] 54 VA# [002] 54 Phase III registrational 54 PREOS R 54 Nexavar 54 ACTEMRA TM 54 PSMA ADC